Furthermore, given the poor median survivals and options for long-term remission or cure in CML blast crisis
, prompt and accurate diagnosis of this disease is imperative.
1 CML in blast crisis
is usually associated with a history of a chronic phase with basophilia and splenomegaly, as well as the BCR-ABL fusion gene.
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis
and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
These findings indicate that the loss of miR-328 is probably essential for progression from the chronic phase of the disease to the blast crisis
stage," said principal investigator Danilo Perrotti, associate professor of molecular virology, immunology and medical genetics and a member of the Ohio State University Comprehensive Cancer Center-Arthur G.
All patients with blast crisis
relapsed within six months (Talpaz et al.
CML progresses through three distinct phases: the chronic phase (typically lasting from four to five years), the accelerated phase (typically lasting from six to 18 months) and blast crisis
(typically lasting from three to six months).
Researchers also studied the effect of Glivec on patients in blast crisis
- 38 had myeloid blast crisis
and 20 had acute lymphocytic leukemia or lymphoid blast crisis
The natural history of CML evolves through a chronic and accelerated phase and terminates in blast crisis
After a chronic phase of production of too many white blood cells, CML typically evolves to the more aggressive phases referred to as accelerated phase and blast crisis
Toluidine blue (TB) is a basic dye that helps in identification of myeloid blasts showing differentiation towards basophils, which may be seen in acute basophilic leukemia, basophilic blast crisis
of chronic myeloid leukemia (CML) and AML with basophilia.
Emerging evidence from a single European centre study indicates that resistance to imatinib mesylate may occur in approximately 25% of chronic phase CML patients, 41% of accelerated phase patients and 92% of blast crisis
4% of those on imatinib progressed to the accelerated phase or blast crisis
of the disease, said lead investigator Dr.